These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 3315594)

  • 21. Comparative tolerance and complications in a multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Rothbard RL
    Drugs; 1987; 33 Suppl 3():276-8. PubMed ID: 3315606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
    Monassier JP; Hanssen M
    Drugs; 1987; 33 Suppl 3():282-5. PubMed ID: 3315608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An interim report of a double-blind placebo-controlled recanalisation study of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Timmis AD; Griffin B; Crick JC; Flax JS; Sowton E
    Drugs; 1987; 33 Suppl 3():146-50. PubMed ID: 3315582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC).
    Johnson ES; Cregeen RJ
    Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised multicentre trial of anisoylated plasminogen streptokinase activator complex versus heparin. Interim results.
    Meinertz T; Kasper W
    Drugs; 1987; 33 Suppl 3():223-6. PubMed ID: 3315597
    [No Abstract]   [Full Text] [Related]  

  • 26. Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.
    Kasper W; Meinertz T; Wollschläger H; Bonzel T; Chen C; Hofmann T; Zeiher A; Drexler H; Just H
    Drugs; 1987; 33 Suppl 3():112-6. PubMed ID: 3315575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary safety and tolerance data obtained in the comparative study of anisoylated plasminogen streptokinase activator complex versus heparin.
    Croydon EA
    Drugs; 1987; 33 Suppl 3():293-6. PubMed ID: 3315611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.
    Jackson D
    Drugs; 1987; 33 Suppl 3():104-11. PubMed ID: 3315574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Samama M; Conard J; Verdy E; van Dreden P; Nguyen G; Combrisson A; Acar J
    Drugs; 1987; 33 Suppl 3():268-74. PubMed ID: 3315605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous bolus application of streptokinase and of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Clinical and haemostaseological findings.
    Hellstern P; Doenecke P; Köhler M; Schwerdt H; Ozbek C; Miyashita C; Bette L; Wenzel E
    Drugs; 1987; 33 Suppl 3():183-5. PubMed ID: 3315589
    [No Abstract]   [Full Text] [Related]  

  • 31. Left ventricular function after anisoylated plasminogen streptokinase activator complex.
    Been M; Muir AL; de Bono DP
    Drugs; 1987; 33 Suppl 3():191-7. PubMed ID: 3315591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.
    Lancet; 1992 Mar; 339(8796):753-70. PubMed ID: 1347801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.
    Hoffmann JJ; Bonnier JJ; de Swart JB; Custers P; Vijgen M
    Drugs; 1987; 33 Suppl 3():242-6. PubMed ID: 3315602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coronary thrombolysis during acute myocardial infarction by intravenous BRL 26921, a new anisoylated plasminogen-streptokinase activator complex.
    Kasper W; Meinertz T; Wollschläger H; Bonzel T; Wolff P; Drexler H; Hofmann T; Zeiher A; Just H
    Am J Cardiol; 1986 Sep; 58(6):418-21. PubMed ID: 3529908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Achievement of coronary artery patency by use of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Hillis WS; Hornung RS; Hogg KJ; Hockings N; Burns JM; Dunn FG
    Drugs; 1987; 33 Suppl 3():117-23. PubMed ID: 3315576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of reperfusion on electrocardiographic and enzymatic infarct size: results of a randomized multicenter study of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) versus intracoronary streptokinase in acute myocardial infarction.
    Hackworthy RA; Sorensen SG; Fitzpatrick PG; Barry WH; Menlove RL; Rothbard RL; Anderson JL
    Am Heart J; 1988 Oct; 116(4):903-14. PubMed ID: 3051985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of thrombolytic therapy with anisoylated plasminogen streptokinase activator complex on the indicators of myocardial salvage.
    Buchalter MB; Bourke JP; Jennings K; Adams PC; Kenmure AC; Hah CW; Reid DS
    Drugs; 1987; 33 Suppl 3():209-15. PubMed ID: 3315593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised placebo-controlled pilot dose-response study with anisoylated plasminogen streptokinase activator complex in acute coronary artery occlusions.
    Leizorovicz A; Durrieu G; Boissel JP
    Drugs; 1987; 33 Suppl 3():133-7. PubMed ID: 3315579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent.
    Anderson JL
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):22B-27B. PubMed ID: 3312369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrinogen concentration and coronary artery reperfusion after intravenous anisoylated plasminogen streptokinase activator complex or intracoronary streptokinase therapy.
    Marder VJ; Kinsella PA; Brown MJ
    Drugs; 1987; 33 Suppl 3():237-41. PubMed ID: 3315601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.